

# Widening use of dexamethasone implant for the treatment of macular edema

Vincenza Bonfiglio  
Michele Reibaldi  
Matteo Fallico  
Andrea Russo  
Alessandra Pizzo  
Stefano Fichera  
Carlo Rapisarda  
Iacopo Macchi  
Teresio Avitabile  
Antonio Longo

Department of Ophthalmology,  
University of Catania, Catania, Italy

**Abstract:** Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated in a biodegradable copolymer to release the active ingredient within the vitreous chamber for up to 6 months after an intravitreal injection, allowing a prolonged interval of efficacy between injections with a good safety profile. Various other ocular pathologies with inflammatory etiopathogeneses associated with macular edema have been treated by DEX implant, including neovascular age-related macular degeneration, Irvine–Gass syndrome, vasoproliferative retinal tumors, retinal telangiectasia, Coats’ disease, radiation maculopathy, retinitis pigmentosa, and macular edema secondary to scleral buckling and pars plana vitrectomy. We undertook a review to provide a comprehensive collection of all of the diseases that benefit from the use of the sustained-release DEX implant, alone or in combination with concomitant therapies. A MEDLINE search revealed lack of randomized controlled trials related to these indications. Therefore we included and analyzed all available studies (retrospective and prospective, comparative and non-comparative, randomized and nonrandomized, single center and multicenter, and case report). There are reports in the literature of the use of DEX implant across a range of macular edema-related pathologies, with their clinical experience supporting the use of DEX implant on a case-by-case basis with the aim of improving patient outcomes in many macular pathologies. As many of the reported macular pathologies are difficult to treat, a new treatment option that has a beneficial influence on the clinical course of the disease may be useful in clinical practice.

**Keywords:** macular edema, dexamethasone, intravitreal, implant, corticosteroids

## Introduction

The sustained-release intravitreal (IV) 0.7 mg dexamethasone (DEX) implant (Ozurdex<sup>®</sup>, Allergan Pharmaceuticals, Irvine, CA, USA) is approved in Europe for the treatment of macular edema related to the following diseases: diabetic retinopathy, branch retinal vein occlusion or central retinal vein occlusion, and non-infectious uveitis.<sup>1</sup>

DEX is one of the 3 most commonly used intraocular corticosteroids together with triamcinolone acetonide (TA) and fluocinolone acetonide. However, compared with these, DEX differs in its pharmacokinetics and pharmacodynamics properties due to certain biological effectiveness: different glucocorticoid receptor binding affinity (DEX > fluocinolone > triamcinolone) and different anti-inflammatory activities (DEX = fluocinolone and is 5 times more active than triamcinolone).<sup>1,2</sup> The advantage of a DEX implant, containing micronized, preservative-free DEX 0.7 mg in a biodegradable copolymer of polylactic-co-glycolic acid (which eventually breaks down

Correspondence: Vincenza Bonfiglio  
Department of Ophthalmology,  
University of Catania, Via S Sofia 76,  
95100, Catania, Italy  
Tel +39 095 378 1291  
Fax +39 095 378 1288  
Email enzabonfiglio@gmail.com

into carbon dioxide and water), is the release of the active ingredient within the vitreous chamber for up to 6 months after an IV injection. All these aforementioned features allow reduction in the frequency of injections with benefit in terms of hospital and patient resource saving, including diminished complications related to injection procedure (eg, retinal detachment, endophthalmitis, lens iatrogenic injury, etc). However, in real life it has been shown that a shorter-interval re-treatment is required because of the loss of the drug's effectiveness before 6 months, with a reported range varying from 4 to 5.9 months.<sup>3,4</sup> Another relevant pharmacological aspect, as demonstrated by experimental studies, is the reduction of IV drugs half-life in vitrectomized eyes compared with non-vitrectomized ones, making their use ineffective.<sup>5</sup> On the contrary, DEX implant has the advantage of maintaining the same half-life and, therefore, the same pharmacological properties in both vitrectomized and non-vitrectomized eyes.<sup>6–8</sup>

Regarding complications related to the use of DEX implant, pivotal studies and real-life studies have confirmed a good safety profile with only a few complications: cataract progression in the range from 29.8%<sup>9</sup> to 67.9%,<sup>10</sup> closely related to the number of implants received, and an increase of intraocular pressure (IOP) >10 mmHg from baseline reported in a range of 15.4%<sup>9</sup> and 27.7%<sup>10</sup> of cases. There are several reviews collecting literature data about the approved use of sustained-release DEX implants. However, there are various ocular pathologies with inflammatory etiopathogeneses associated with macular edema, such as: neovascular age-related macular degeneration (nAMD); Irvine–Gass syndrome (IGS); vasoproliferative retinal tumors (VPRTs); retinal telangiectasia and Coats' disease; radiation maculopathy; retinitis pigmentosa; macular edema secondary to scleral buckling and pars plana vitrectomy (PPV), all of which have been treated by DEX implant.

The aim of this review was to provide a systematic collection of all of the diseases that benefit from the use of the sustained-release DEX implant alone or in combination with concomitant therapies in order to provide a valuable therapy option for these diseases in clinical practice.

## Methods

MEDLINE databases for the period 2009 to September 2016 were searched by using the medical subject heading “Dexamethasone intravitreal implant/Ozurdex” and the keywords “macular edema, age-related macular degeneration, Irvine–Gass, pseudophakic cystoid macular edema,

post-operative macular edema, PPV, scleral buckling, retinitis pigmentosa, prostaglandin, radiation macular edema, telangiectasia.” Studies were limited to the English language. Because randomized controlled trials on these topics were lacking, all studies (retrospective and prospective, comparative and non-comparative, randomized and nonrandomized, single center and multicenter, and case reports) were analyzed. Aims, and anatomical and functional outcomes, and complications after DEX implant were analyzed.

## nAMD

Approved first-line therapy for nAMD is based on the use of anti-vascular endothelial growth factor (VEGF) IV injections such as pegaptanib, ranibizumab, and aflibercept. However, there are patients who have a non-complete response to anti-VEGF injections as well as patients who, after an optimal functional and anatomical response, develop tachyphylaxis.<sup>11</sup> The explanation for this incomplete response lies in the multifactorial pathogenesis of AMD, which involves VEGF, inflammation, and oxidative stress, as seen in histological studies performed on neovascular membranes after their surgical excision. Neovascular membrane growth in the sub-retinal space is stimulated by activated macrophages (and other inflammatory cells secreting cytokines) and enzymes that can damage the Bruch's membrane.<sup>12</sup> Therefore, inflammation is another potential target of nAMD treatment that could be counteracted by the use of corticosteroids.

Combination therapy consisting of anti-VEGF therapy and a corticosteroid relies on the use of drugs with different mechanisms of action, and could allow the reduction of anti-VEGF IV injection frequency and therefore, improve long-term efficacy and safety while reducing scarring results.<sup>13–16</sup> Using combination therapies to treat nAMD dates back to photodynamic therapy (PDT), when it was associated with the IV TA injection.<sup>17,18</sup> However, side effects due to IV TA, such as cataract progression and increased IOP, sometimes resistant to medical therapy, halted these procedures despite anatomical and functional benefits.<sup>19</sup> Cataract surgery has been reported in around 45.2% of eyes that underwent triamcinolone injection,<sup>19</sup> and ocular hypertension (IOP >21 mmHg) in around 44.6% of eyes, with IOP-lowering surgery required in 0.3% of eyes.<sup>20</sup>

The LuceDex study<sup>21</sup> was the first study using the IV DEX injections (500 mg in 0.05 mL), followed by IV ranibizumab (4 monthly injections of 0.5 mg in 0.05 mL) that was compared with IV ranibizumab monotherapy (Group 2; total

37 patients). After 4 consecutive months, in both groups, ranibizumab pro re nata treatment was administered if signs of lesion activity were present. The results of this study showed a clear benefit for combination therapy, with reduction in the dimension of the choroidal neovascular membrane, detected by fluorescein angiography, improvement in visual acuity, and reduced treatment frequency. Central macular thickness (CMT) and volume reductions were also observed, although these changes were not statistically significant.

After the approval of the DEX implant, several authors evaluated its efficacy in nAMD<sup>22–25</sup> (Table 1). Compared with ranibizumab monotherapy, studies showed no long-term improvement of best corrected visual acuity (BCVA) and reduction of CMT;<sup>22–25</sup> however, DEX implant in some cases allowed a reduced number of anti-VEGF injections.<sup>23,24</sup>

One study<sup>24</sup> reported an incidence of cataract surgery of 9% in ranibizumab-treated eyes and 33% in eyes receiving 2 DEX implants. The incidence of ocular hypertension ranged from 15% to 42%,<sup>22–25</sup> all treated with topical hypotonicizing therapy.

## IGS

The most likely physiopathological hypothesis for IGS is an inflammatory response instigated by the inflammatory mediators released during and after surgical procedures, causing alterations to the blood–retinal barrier. Many risk factors have been identified, such as posterior capsule rupture and vitreous loss, as well as the use of iris retractors, the presence of an epiretinal membrane, a vein occlusion, a history of uveitis or diabetes and the use of prostaglandin eye drops.<sup>26</sup>

First-line treatment for IGS involves the use of different therapies: topical nonsteroidal anti-inflammatory drugs (NSAIDs), oral acetazolamide, and topical corticosteroids. In patients resistant to such treatments, the following off-label treatment options have been tried:<sup>26–32</sup>

- IV anti-VEGF
- Subcutaneous interferon  $\alpha 2a$  injections
- IV infliximab (anti-tumor necrosis factor- $\alpha$ )
- Intra-, retro-, and peribulbar corticosteroids
- PPV

Several authors have evaluated the efficacy of DEX implant for chronic IGS<sup>33–45</sup> (Table 2).

Most of the studies had a 6-month follow-up; they showed a significant improvement in BCVA and a significant reduction in CMT with 1 DEX implant. Two prospective studies<sup>38,43</sup> of DEX compared with IVTA showed similar functional effects and anatomical effects: one found a lower

incidence of ocular hypertension in the DEX group (at 6 months 0% vs 20%,  $P=0.044$ ).

A retrospective long-term study<sup>44</sup> that included 58 cases of IGS in a total of 100 eyes found that efficacy was maintained at 24 months, after a mean number of 1.77 DEX implants in the first year and 1.70 in the second year. At 24 months, an IOP  $>25$  mmHg was found in 6.2% of the patients, all treated with hypotensive eye drops and not requiring filtering surgery.<sup>44</sup>

## VPRTs

Several approaches have been used to treat VPRTs, including cryotherapy, laser photocoagulation, PDT, IV anti-VEGF, plaque brachytherapy, and PPV.<sup>45–47</sup>

VPRTs treated by DEX and PDT were reported in 3 cases<sup>48</sup> (Table 3). Total involution of the tumor was reported within 2 months and regression of exudates continued for several months, leaving fibrotic scar tissue in the inferior half of the retina.<sup>48</sup>

## Retinal telangiectasia and Coats' disease

### Retinal telangiectasia

Yannuzzi et al<sup>49</sup> have recently classified different forms of idiopathic macular telangiectasia: aneurismal telangiectasia, idiopathic perifoveal telangiectasia, and occlusive telangiectasia. Although several approaches have been suggested for the treatment of idiopathic macular telangiectasia (including laser photocoagulation,<sup>50</sup> PDT,<sup>51</sup> IV anti-VEGF,<sup>52</sup> PPV<sup>53</sup>), no treatment has yet been shown to provide a consistent effect on visual acuity. Also, corticosteroids have been used to treat these vascular pathologies due to their biological effect<sup>54</sup> and DEX implant can be assumed to be an useful therapeutic device,<sup>55,56</sup> which can also be administered in pediatric patients<sup>57</sup> (Table 4).

In these cases, with a longer follow-up, multiple DEX implants were performed, at each time successfully (leading to BCVA improvement and CMT reduction).<sup>56–58</sup>

### Coats' disease

In Coats' disease, ablative therapy by laser photocoagulation and cryotherapy is the gold standard of treatment<sup>57</sup> with photocoagulation preferred over cryotherapy in cases with little or no subretinal fluid.<sup>57</sup> IV therapies such as anti-VEGF and steroids could be used to improve anatomic and visual outcomes,<sup>58,59</sup> in particular, in combination with ablative therapies. IV corticosteroids, including DEX implant<sup>60–62</sup>

**Table 1** Published studies on the use of DEX implant for age-related macular degeneration

Reference	Study design	No of eyes	Previous treatment	Treatment	Follow-up	Retreatment	BCVA	CMT	Complications
Calvo et al <sup>22</sup>	Retrospective	7 refractory	3 anti-VEGF	1 DEX + ranibizumab monthly	6 months	2 DEX (28.5%)	From 0.53±0.13 logMAR to 3 months: 0.45±0.3 (P=0.23) 6 months: 0.52±0.2 (P=0.23)	From 273.14±50.94 µm to 3 months: 241.5±36.6 µm; (P=0.04) 6 months: 260.71±58.51 µm (P=0.40)	3 ocular hypertension (42.8%) (27–32 mmHg)
Kuppermann et al <sup>23</sup>	Prospective multicenter randomized	243	115 naïve:	58 DEX + ranibizumab vs 57 sham + ranibizumab PRN	6 months	3.15 DEX + ranibizumab PRN	Naïve Change from baseline: DEX: +0.3 to +2.7 L Sham: -0.5 to +2.6 L	Naïve Change from baseline: DEX: -12.61±96.4 µm Sham: -34.70±106.6 µm (P<0.05)	DEX 18.2% IOP ≥25 mmHg
Rezar-Dreindl et al <sup>24</sup>	Prospective randomized	40	128 prev treatment	65 DEX + ranibizumab vs 63 sham + ranibizumab PRN	12 months	3.37 sham + ranibizumab	Prev treatment Change from baseline: DEX: +0.4 to +2.4 L Sham: -0.3 to 2.6 L	Prev treatment Change from baseline: DEX: -1.74±54.4 µm Sham: +6.84±84.9 µm (P=ns)	Sham 5.1% IOP ≥25 mmHg (P=0.002)
Rezar-Dreindl et al <sup>24</sup>	Prospective randomized	40	5.6±3.4 ranibizumab	20 ranibizumab	12 months	7.95 ranibizumab P=0.042	From 62 to 68 L (P=0.2)	From 485 µm to 6 months: 426 µm 12 months: 453 µm (P=0.38)	9% cataract surgery 0% IOP >30 mmHg
Chaudhary et al <sup>25</sup>	Prospective multicenter randomized	10	6.7±4.4 ranibizumab	20 ranibizumab + DEX	6 months	5.5 ranibizumab + 2 DEX (18 eyes)	68 to 71 L	From 439 µm to 6 months: 375 µm 12 months: 368 µm	33% cataract surgery 15% IOP >30 mmHg
Chaudhary et al <sup>25</sup>	Prospective multicenter randomized	10	NR	5 ranibizumab	6 months	6.2±2.3	Change from baseline: 10.8±13.2 L	Change from baseline: 31.7%±17.5% to 13.3%±27.0% (P=0.236)	1 IOP >30 mmHg
Chaudhary et al <sup>25</sup>	Prospective multicenter randomized	10	NR	5 ranibizumab + DEX	6 months	5.8±1.8 (P=0.766)	3.0±10.5 L (P=0.331)		

**Abbreviations:** BCVA, best corrected visual acuity; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; Naïve, previously untreated; NR, not reported; ns, not significant; prev treatment, previously treated; PRN, pro re nata; VEGF, vascular endothelial growth factor.

**Table 2** Published studies on the use of DEX implant for Irvine–Gass syndrome

Reference	Study design	No of eyes	Previous treatment	Treatment	Follow-up	Retreatment	BCVA	CMT	Complications
Williams et al <sup>33</sup>	Prospective multicenter randomized	41 uveitis + IGS (27)	Laser Medical therapy	DEX 0.7 mg or DEX 0.35 mg observation	6 months	NR	53.8% improvement ≥ 10 L after 3 months ( <i>P</i> =0.029) 41.7% improvement ≥ 10 L after 3 months ( <i>P</i> =0.117) 14.3% improvement ≥ 10 L after 3 months	NR	31% IOP >25 mmHg (0.7 mg)
Meyer and Schönfeld <sup>34</sup>	Case report	1	3 IVT 0.4 mg dexamethasone	I DEX	4 months	NR	From 0.30 to 0.8 (for at least 3 months)	From 393 μm to 212 μm (for at least 3 months)	NR
Dutra Medeiros et al <sup>35</sup>	Retrospective	9	CAIs Topical NSAIDs Corticosteroids IVT anti-VEGF IVT TA	I DEX	6 months	NR	From 0.62±0.15 logMAR to 1 month: 0.47±0.21 ( <i>P</i> =0.008) 3 months: 0.37±0.24 ( <i>P</i> =0.001) 6 months: 0.37±0.26 ( <i>P</i> =0.002)	From 542.22±134.78 μm to 1 month: 350.88±98.71 μm ( <i>P</i> =0.001) 3 months: 319.22±60.96 μm ( <i>P</i> =0.002) 6 months: 398.33±127.89 μm ( <i>P</i> =0.031)	NR
Brynskov et al <sup>36</sup>	Case report	1	TA Sub-Tenon's 5 Ranibizumab IVT	DEX	12	Second DEX (187 days later)	First DEX: from 78 ETDRS letters to 76 Second DEX: from 76 ETDRS letters to 85 RE: from 20/70 to 50 days 20/20	First DEX: from 541 to 219 μm (after 83 days) Second DEX: from 436 to 229 μm (after 56 days) -369 μm after 7 days	NR
Fencia et al <sup>37</sup>	Case report	1 patient (2 eyes)	RE: topical NSAIDs Oral indomethacin 3 peribulbar methylprednisolone LE: topical NSAIDs Oral indomethacin Ranibizumab IVT	RE: DEX + Ranibizumab IVT (84 days later) LE: DEX	NR	RE: IDEX +1 ranibizumab IVT (84 days later) +1 DEX (2 months later IVT ranibizumab)	LE: from 20/40 to 80 days 20/20	NR	NR
Dang et al <sup>38</sup>	Prospective, nonrandomized, comparative	18	Topical steroids Topical NSAIDs	DEX	6	2 DEX (5 months after)	1 month: VAI 44% <i>P</i> =0.625 vs TA 2 months: VAI 39% <i>P</i> =0.941 vs TA 3 months: VAI 39% <i>P</i> =0.553 vs TA 6 months: VAI 33% <i>P</i> =0.856 vs TA	1 month: -175 μm (mean change), <i>P</i> =0.783 vs TA 2 months: -145 μm (mean change), <i>P</i> =0.044 vs TA 3 months: -126 μm (mean change), <i>P</i> =0.049 vs TA	DEX 1 month: 6% IOP>21 mmHg 2 months: 6% IOP>21 mmHg 3 months: 6% IOP>21 mmHg 6 months: 0% IOP>21 mmHg ( <i>P</i> =0.044)

(Continued)

Table 2 (Continued)

Reference	Study design	No of eyes	Previous treatment	Treatment	Follow-up	Retreatment	BCVA	CMT	Complications
		25		TA	6.27±0.47	15 I IVT TA 9.2 IVT TA 1.3 IVT TA	1 month: VAI 52% 2 months: VAI 40% 3 months: VAI 48% 6 months: VAI 36%	6 months: -125 µm (mean change), P=0.812 vs TA 1 month: -193 µm (mean change) 2 months: -95 µm (mean change) 3 months: -173 µm (mean change) 6 months: -140 µm (mean change)	TA 1 month: 12% IOP>21 mmHg 2 months: 12% IOP>21 mmHg 3 months: 20% IOP>21 mmHg 6 months: 20% IOP>20 mmHg
Furino et al <sup>39</sup>	Retrospective	11	NR	I DEX	6.27±0.47	NR	From 20/40 to 20/22 (P<0.0001)	From 462±100 µm to 276±8 µm (P<0.0001)	NR
Al Zamir <sup>40</sup>	Retrospective	11	Oral CAIs Topical NSAIDs Corticosteroids IVT anti-VEGF IVTA	I DEX	6	NR	From 0.58±0.17 logMAR to 1 month: 0.37±0.16 logMAR (P=0.008) 3 months: 0.20±0.13 logMAR (P=0.001) 6 months: 0.21±0.15 logMAR (P=0.002)	From 513.8±134.9 µm to 371.6±91.9 µm (P=0.001) 3 months: 302.6±50.9 µm (P=0.002) 6 months: 308.0±54.5 µm (P=0.031)	NR
Khurana et al <sup>41</sup>	Prospective case series	6	Topical NSAIDs	I DEX	NR	NR	6 months: +14 L (P=0.03)	1 month: -100 µm (mean change) (P<0.01) 6 months: -72 µm (mean change) (P=0.004)	NR
Ortega-Evangelico and Diago Sempere <sup>42</sup>	Retrospective	4	NR	I DEX	6	NR	From 0.3 to 1 month: 0.575 logMAR (mean) 3 months: 0.575 logMAR (mean)	From 414 µm to 1 month: 330.25 µm (mean change) 3 months: 346.75 µm (mean change)	NR

Drug Design, Development and Therapy downloaded from <https://www.dovepress.com/> by 18.234.247.75 on 24-Jan-2021  
For personal use only.

Mylonas et al <sup>43</sup>	Prospective randomized	29	NR	14 IVTA	6	19 second IVTA	From 63±13 L to 1 month: 73±11 L (P=0.001) 3 months: 73±11 L (P=0.001) 6 months: 71±13 L (P=0.001)	From 516±121 µm to 1 month: 355±59 µm (P=0.003) 3 months: 389±89 µm (P=0.001) 6 months: 365±74 µm (P=0.002)
				15 DEX			From 60±10 L to 1 month: 73±10 L (P<0.001) 3 months: 72±11 L (P<0.001) 6 months: 66±13 L (P=0.009)	From 548±110 µm to 1 month: 357±69 µm (P<0.001) 3 months: 391±102 µm (P<0.001) 6 months: 504±159 µm (P=0.05)
EPISODIC 2 study <sup>44</sup>	Retrospective	58 IGS of 100 overall	NR	I DEX	24 months (25 eyes)	1.7 first year 1.657 second year	Baseline mean 58.5±15.6 L 18 months: 66.9 (±18.3) L 24 months: 62.3 L (±14.3)	Baseline 518.13±117.2 µm 18 months: 346.9±115.7 µm 24 months: 340.2±116 µm -176 µm (P<0.001) -182.7 µm (P<0.001)
Sacchi et al <sup>45</sup>	Case report	I	Sub-Tenon's betamethasone	I DEX	6 months	NR	From 20/40 to 1 month: 20/30	NR IOP >21 mmHg

**Abbreviations:** BCVA, best corrected visual acuity; CAIs, carbonic anhydrase inhibitors; CMT, central macular thickness; DEX, dexamethasone implant; ETDRS, Early Treatment Diabetic Retinopathy Study; IGS, Irvine-Gass syndrome; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone acetate; L, ETDRS letters; LE, left eye; NR, not reported; NSAIDs, nonsteroidal anti-inflammatory drugs; RE, right eye; TA, triamcinolone acetate; VAI, visual acuity improvement >10 L; VEGF, vascular endothelial growth factor.

**Table 3** DEX in vasoproliferative retinal tumors

Reference	Study design	No of eyes	Previous treatment	Treatment	Follow-up	Retreatment	BCVA	CMT	Complications
Cebeci et al <sup>48</sup>	Case report	3	IVT BEV Laser photocoagulation	DEX	12 months	1 DEX + PDT (1 week after)	From 20/25 to 20/40	NR	1 subcapsular cataract

**Abbreviations:** BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IVT, intravitreal; NR, not reported; PDT, photodynamic therapy.

have been used to reduce intraocular inflammation, tighten capillary walls, and suppress cell proliferation, also having anti-VEGF properties,<sup>58</sup> (Table 5).

In one case, DEX implant led to a resolution of the exudative retinal detachment allowing laser photocoagulation of telangiectatic vessels.<sup>63</sup> In other cases, final BCVA was influenced by subfoveal fibrosis, present at the time of the treatment<sup>58</sup> or existing over a long-term.<sup>60</sup>

### Radiation maculopathy

Several treatments have been proposed for radiation maculopathy, including laser photocoagulation, PDT, periocular injection of TA, IV anti-VEGF and, most recently, DEX implant (Table 6).<sup>63–68</sup> All of these studies demonstrated a significant anatomical benefit with DEX implant in cases of recalcitrant radiation macular edema, with significant changes in visual acuity in most of the cases. Two comparative studies<sup>65,67</sup> comparing DEX implant with anti-VEGF therapy, found no difference in outcomes, and a reduction in the number of injections in DEX-treated eyes.<sup>65</sup>

IOP increased in some eyes,<sup>63,64,66</sup> all successfully treated by topical hypotonizing therapy. Cataract development

in these cases<sup>64–66</sup> could be caused by DEX or the radiation therapy.

### Retinitis pigmentosa

The exact pathogenesis of macular edema, whether it is related to chronic and low-grade inflammatory process<sup>69</sup> or to autoimmune process as antiretinal antibodies<sup>70</sup> or to the failure of the retinal pigment epithelium pumping mechanism, is unknown as yet.<sup>71</sup> Treatments attempted include topical and systemic administration of CAI,<sup>71</sup> NSAIDs, retinal laser photocoagulation, vitrectomy surgery,<sup>72</sup> and IV anti-VEGF.<sup>73</sup> Also, IV corticosteroids injections have been performed as these drugs may modulate the inflammatory mediators and the autoimmune process.<sup>74–76</sup>

The studies reporting on the use of DEX in macular edema related to retinitis pigmentosa consist of case report studies, which include only a few eyes (Table 7).<sup>77–80</sup> Nevertheless, an anatomical and functional improvement has been shown, but a relapse of macular edema occurred before 6 months from the implant<sup>77</sup> and an additional DEX was required in some cases.<sup>77,78</sup> DEX implant proved to be safe with an IOP rise >21 mmHg recorded in only one eye.<sup>78</sup>

**Table 4** Published studies on the use of DEX implant for retinal telangiectasia

Reference	Study design	No of eyes	Previous treatment	Treatment	Follow-up	Retreatment	BCVA	CMT	Complications
Sandali et al <sup>55</sup>	Case report	1	3 BEV IVT	DEX	15 months	2 DEX	From 20/32 to 1 month: 20/20	From 398 $\mu$ m to 1 month: 250 $\mu$ m	NR
Loutfi et al <sup>56</sup>	Case report	1	3 BEV IVT 1 IVTA	DEX	NR	3 DEX	From 0.3 to 0.59 logMAR: 6 weeks after 1st DEX; from 0.3 to 0.64 logMAR: 6 weeks after 2nd DEX; from 0.3 to 0.78 logMAR: 2 weeks after 3rd DEX	From 397 $\mu$ m to 286 $\mu$ m: 6 weeks after 1° DEX; 6 weeks after 2° DEX: 279 $\mu$ m; 2 weeks after 3° DEX: 279 $\mu$ m	NR
Lei and Lam <sup>62</sup>	Retrospective	1	8 ranibizumab IVT + laser	DEX	17 months	4 DEX	From 1 to 52 weeks: 0.5 logMAR	From 607 $\mu$ m to 52 weeks: 346 $\mu$ m	NR

**Abbreviations:** BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IVT, intravitreal; IVTA, intravitreal triamcinolone acetonide; NR, not reported.



**Table 5** DEX implant in Coats' disease

Reference	Study design	No of eyes	Previous treatment	Primary treatment	Follow-up	Retreatment	BCVA	CMT	Complications
Saatci et al <sup>60</sup>	Case report	2	5 ranibizumab IVT + laser photocoagulation in 1 eye	DEX in one patient DEX + laser photocoagulation in the other patient	12 months 6 months	NR	Unchanged From 2/10 to 3/10	NR	IOP rise >25 mmHg in both eyes
Martínez-Castillo et al <sup>61</sup>	Case report	1	None	DEX + laser photocoagulation	12 months	NR	From 20/200 to 20/25	NR	None
Lei and Lam <sup>62</sup>	Retrospective chart review	1	3 BEV IVT + laser photocoagulation	DEX	16 months	3 DEX	From 1.3 to 52 weeks: 1.8 logMAR	From 82.1 $\mu$ m to 52 weeks: 589 $\mu$ m	None

**Abbreviations:** BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; IVT, intravitreal; NR, not reported.

**Table 6** Published studies on the use of DEX implant for radiation maculopathy

Reference	Study design	No of eyes	Previous treatment	Primary treatment	Follow-up	Retreatment	BCVA	CMT	Complications
Baillif et al <sup>63</sup>	Retrospective	5	None	DEX	6.4 months	3 eyes: 1 DEX 2 eyes: 2 DEX	From 41 L to 2 months: 47 L	From 487.1 $\mu$ m to 2 months: 331.2 $\mu$ m	1 eye IOP >25 mmHg
Caminal et al <sup>64</sup>	Retrospective	12	2 laser 2 VEGF IVT 5 laser + anti-VEGF IVT	DEX	8.2 $\pm$ 7.8 months	1 eye: 2 DEX	From 1 $\pm$ 0.58 to 0.8 $\pm$ 1.58 logMAR (P=0.091)	From 416 $\pm$ 263 to 254 $\pm$ 170 $\mu$ m (P=0.016)	1 eye cataract 1 eye IOP rise
Russo et al <sup>65</sup>	Retrospective comparative	16	NR	8 DEX 8 ranibizumab IVT	Range 7–52 months	2.4 $\pm$ 0.9 DEX (24 months) (P=0.018 vs ranibizumab) 6 $\pm$ 1.8 ranibizumab (24 months)	DEX: from 0.45 $\pm$ 0.18 to last follow-up: 0.27 $\pm$ 0.15 logMAR (P=0.011) Ranibizumab: from 0.49 $\pm$ 0.14 to last follow-up: 0.34 $\pm$ 0.13 logMAR (P=0.012)	From 437 $\pm$ 71 $\mu$ m to last follow-up: 254 $\pm$ 44 $\mu$ m (P=0.012) From 459 $\pm$ 81 $\mu$ m to last follow-up: 243 $\pm$ 58 $\mu$ m (P=0.012) (P=0.721 vs ranibizumab)	NR

(Continued)

Table 6 (Continued)

Reference	Study design	No of eyes	Previous treatment	Primary treatment	Follow-up	Retreatment	BCVA	CMT	Complications
Bui et al <sup>66</sup>	Retrospective	2	16 BEV IVT +4 IVTA 7 BEV +1 IVTA	DEX	NR	2 DEX	From 20/60 Snellen to 3 months: unchanged From 20/400 Snellen to 3 months: unchanged DEX: 0.8 logMAR, unchanged BEV: 0.8 logMAR, 1 month, after last IVT 0.7 logMAR IVTA: 0.8 logMAR, unchanged	From 456 to 238 $\mu$ m after first DEX; 277 $\mu$ m after second DEX From 618 to 336 $\mu$ m DEX: from 440 $\mu$ m to 4 weeks 265 $\mu$ m (P=0.049) BEV: from 479 $\mu$ m to 4 weeks 362 $\mu$ m (P=0.01) IVTA: from 454 $\mu$ m to 4 weeks 314 $\mu$ m (P=0.034)	1 cataract surgery 2 IOP rise
Seibel et al <sup>67</sup>	Retrospective comparative	5 DEX 38 BEV 35 IVTA	None	DEX BEV IVTA	At least 12 months	1-2 DEX BEV (range 1-10) IVTA (range 1-3)			NR
Tarmann et al <sup>68</sup>	Retrospective	4	BEV IVT in 3 eyes BEV IVT + panretinal laser photocoagulation and IVTA in 1 eye	DEX	NR	NR	From 20/100 Snellen to 2-4 weeks 20/50 to 10 weeks 20/80 Snellen to 14-17 weeks: 20/100 Snellen	From 616 $\mu$ m to 2-4 weeks: 399 $\mu$ m 10 weeks: 393 $\mu$ m 14-17 weeks: 568 $\mu$ m	1 eye IOP >25 mmHg

**Abbreviations:** BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IVT, intravitreal; IVTA, intravitreal triamcinolone acetate; NR, not reported; VEGF, vascular endothelial growth factor.

Table 7 DEX implant in retinitis pigmentosa

Reference	Study design	No of eyes	Previous treatment	Treatment	Follow-up	Retreatment	BCVA	CMT	Complications
Srouf et al <sup>77</sup>	Retrospective	4	CAIs in all cases subtenon TA 1 case NSAIDs in 2 cases	DEX	6 months	2 DEX in 2 eyes after 3 months	From 20/160 to 6 months: 20/125 after 1 DEX	From 443 $\pm$ 185 $\mu$ m to 6 months: 305 $\pm$ 124 $\mu$ m after 1 DEX	None
Ahn et al <sup>78</sup>	Case report	2 eyes of one patient	CAIs Anti-VEGF IVT	DEX	12 months	2 DEX in 1 eye 6 months after DEX	From 20/100 to 12 months: 20/60 RE From 20/150 to 12 months: 20/100 LE	From 631 $\mu$ m to 12 months: 531 $\mu$ m RE From 681 $\mu$ m to 12 months: 499 $\mu$ m LE	IOP rise IOP >21 mmHg
Saatci et al <sup>79</sup>	Case report	2 eyes of one patient	Topical CAIs	1 DEX	7 months	NR	From 2/10 to 1 week: 4/10 both eyes 3 months: 2/10 both eyes	NR	None
Patil and Lotery <sup>80</sup>	Case report	1	Topical CAIs Depo-Medrone Parabolbar Anti-VEGF IVT IVTA Cryotherapy	1 DEX	10 months	NR	From 1.01 logMAR to 6 weeks: 0.89 logMAR	From 559 $\mu$ m to 6 weeks: 271 $\mu$ m	None

**Abbreviations:** BCVA, best corrected visual acuity; CAIs, carbonic anhydrase inhibitors; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone; LE, left eye; NR, not reported; NSAIDs, nonsteroidal anti-inflammatory drugs; RE, right eye; TA, triamcinolone acetate; VEGF, vascular endothelial growth factor.

Table 8 Published studies on the use of DEX implant for other conditions

Reference	Study design	No of eyes	Previous treatment	Primary treatment	Follow-up	Retreatment	BCVA	CMT	Complications
Furino et al <sup>81</sup>	Retrospective	8 PPV + ILM peeling + cataract surgery	Diclofenac sodium and betamethasone drops	DEX	6.75±0.71 month	NR	From 20/50 to 20/23 P<0.00001	From 438±45 µm to 296±49 µm P<0.00001	No eye IOP > 18 mmHg
Taney et al <sup>82</sup>	Retrospective	5 PPV with ERM peeling	Topical prednisolone 1% Topical NSAIDs Subtenon TA IVTA in 1 eye Anti-VEGF IVT in 3 eyes Anti-VEGF IVT 1 eye	DEX	NR	1 DEX in 3 eyes 9 DEX in 1 eye 7 DEX in 1 eye	3 Snellen lines improvement in 3 eyes at 4–6 weeks after DEX 1 Snellen line improvement in 1 eye at 4–6 weeks after DEX No BCVA improvement in 1 eye at 4–6 weeks after DEX 1 eye at 4–6 weeks after DEX	Mean CMT decrease of 106 µm (range 56–155 µm) in 4 eyes at 4–6 weeks after DEX No CMT improvement in 1 eye at 4–6 weeks after DEX Reduction of CMT 2 months after DEX	1 eye IOP >25 mmHg Cataract in 1 out of the 2 phakic eyes
Merkoudis and Granstam <sup>83</sup>	Case report	1 PPV + ILM peeling and C <sub>2</sub> F <sub>6</sub> tamponade + cataract surgery	IVTA Topical NSAIDs Oral CAI	1 DEX	10 months	NR			
Georgalas et al <sup>84</sup>	Case report	1 PPV + ILM peeling cataract surgery	Topical steroids Subtenon steroids Intravitreal steroids	1 DEX	6 months	NR	From counting fingers to 1 week: 6/36	From 640 µm to 1 week: 383 µm	None
Bonfiglio et al <sup>85</sup>	Case report	1 scleral buckling + cryopexy	Oral prednisolone Oral CAI Topical prednisolone Topical NSAIDs TA Subtenon	1 DEX	6 months	NR	From 0.70 to 6 months: 0.20 logMAR	From 510 µm to 6 months: 290 µm	None

**Abbreviations:** BCVA, best corrected visual acuity; CAI, carbonic anhydrase inhibitor; CMT, central macular thickness; DEX, dexamethasone implant; ERM, epiretinal membrane; ILM, inner limiting membrane; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone; NR, not reported; NSAIDs, nonsteroidal anti-inflammatory drugs; PPV, pars plana vitrectomy; TA, triamcinolone acetonide; VEGF, vascular endothelial growth factor.

## DEX implant in macular edema after retinal surgery

DEX implant was used also in case of macular edema secondary to PPV for epiretinal membrane or macular hole or scleral buckling (Table 8).<sup>81–85</sup> In all cases, an anatomical and functional improvement was shown, even though in 2 cases, multiple DEX implants were performed because of recurrent macular edema.<sup>82</sup> Additionally, the use of DEX allowed resolution of severe choroidal inflammation detected in 1 case following scleral buckle surgery.<sup>85</sup>

## Conclusion

The use of DEX implant for all of the aforementioned macular pathologies merits consideration, and the results reported can support the use of DEX implant on a case-by-case basis with the aim of improving patient outcomes in many macular pathologies.

In many of these cases, DEX implant allowed a reduction of CMT with an improvement of BCVA, even if, at long term, many eyes required retreatment because DEX implant started to lose its efficacy, sometimes at 3 months after the injection.

Many of these cases were refractory to previous treatments, and DEX implant was administered as the last treatment option. Consequently, the functional results provided may be influenced by the lateness of DEX implant use. Therefore, considering that many of the reported macular pathologies may be difficult to treat and that some of them are not especially uncommon, having an awareness of a new treatment option and its influence on the clinical course of the disease may represent a great assistance in clinical practice. Furthermore, the use of DEX remains the only solution in treating macular edema in vitrectomized eyes where the efficacy of other IV drug injections, such as anti-VEGF, is lost due to their pharmacokinetic properties.

DEX implant-related adverse events in this expanding-use scenario are consistent with those previously documented for the DEX treatment of diabetic macular edema, uveitis, and retinal vein occlusion.<sup>10,86,87</sup> In the cases that we analyzed, cataract was reported in up to 33% of the eyes after 2 DEX implants,<sup>24</sup> and the occurrence of ocular hypertension (IOP  $\geq$  25 mmHg) from 6%<sup>38</sup> to 31%,<sup>32</sup> all treated with topical therapy.

In conclusion, DEX implant may allow less frequent anti-VEGF treatment<sup>24,65</sup> and therefore, the advantages for the patient are clear: the need to undergo stressful treatment is removed while ocular and systemic adverse effects are reduced.

## Acknowledgments

We thank Ray Hill, an independent medical writer, who provided English-language editing and journal styling before submission on behalf of Health Publishing & Services Srl. Technical editing and publication fees for this manuscript were supported by Allergan.

## Author contributions

All authors contributed to developing the concepts, design, and/or analysis and interpretation of data in this review, writing/revising the manuscript, and approved the final version before submission and agreed to be accountable for all aspects of the work.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Dugel PU, Bandello F, Loewenstein A. Dexamethasone intravitreal implant in the treatment of diabetic macular edema. *Clin Ophthalmol*. 2015;9:1321–1335.
- Yang Y, Bailey C, Loewenstein A, Massin P. Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. *Retina*. 2015;35(12):2440–2449.
- Bezatis A, Spital G, Höhn F, et al. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up – the SOLO study. *Acta Ophthalmol*. 2013;91(5):e340–e347.
- Coscas G, Augustin A, Bandello F, et al. Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. *Eur J Ophthalmol*. 2014;24(1):1–9.
- Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and non vitrectomized eyes. *Retina*. 2005;25(5):556–560.
- Chang-Lin JE, Burke JA, Peng Q. Pharmacokinetics of a sustained release dexamethasone intravitreal implant in vitrectomized and non vitrectomized eyes. *Invest Ophthalmol Vis Sci*. 2011;52(7):4605–4609.
- Shaikh AH, Petersen MR, Sisk RA, Foster RE, Riemann CD, Miller DM. Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusion. *Ophthalmic Surg Lasers Imaging Retina*. 2013;44(1):28–33.
- Adan A, Pelegrín L, Rey A, et al. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. *Retina*. 2013;33(7):1435–1440.
- Haller JA, Bandello F, Belfort R Jr, et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology*. 2011;118(12):2453–2460.
- Boyer DS, Yoon YH, Belfort R Jr, et al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. *Ophthalmology*. 2014;121(10):1904–1914.
- Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2006;355(14):1419–1431.
- Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. *Prog Retin Eye Res*. 2009;28(1):1–18.
- Spaide RF. Rationale for combination therapy in age-related macular degeneration. *Retina*. 2009;29(Suppl 6):S5–S7.

14. Adamis AP. The rationale for drug combinations in age-related macular degeneration. *Retina*. 2009;29(Suppl 6):S42–S44.
15. Couch SM, Bakri SJ. Review of combination therapies for neovascular age-related macular degeneration. *Semin Ophthalmol*. 2011; 26(3):114–120.
16. Das RA, Romano A, Chiosi F, et al. Combined treatment modalities for age related macular degeneration. *Curr Drug Targets*. 2011;12(2): 182–189.
17. Kvant A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. *Invest Ophthalmol Vis Sci*. 1996;37(9):1929–1934.
18. Gallego-Pinazo R, Marín-Lambies C, Marín-Olmos F, et al. Intravitreal dexamethasone as an enhancer for the anti-VEGF treatment in neovascular ARMD: recovering an old ally. *Arch Soc Esp Oftalmol*. 2010; 85(2):79–80.
19. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. *Am J Ophthalmol*. 2006; 141(4):629–637.
20. Roth DB, Verma V, Realini T, Prenner JL, Feuer WJ, Fechtner RD. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. *Ophthalmology*. 2009;116(3): 455–460.
21. Ranchod TM, Ray SK, Daniels SA, Leong CJ, Ting TD, Verne AZ. Luce-Dex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration. *Retina*. 2013;33(8):1600–1604.
22. Calvo P, Ferreras A, Al Adel F, Wang Y, Brent MH. Dexamethasone intravitreal as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab. *Br J Ophthalmol*. 2015;99(6):723–726.
23. Kuppermann BD, Goldstein M, Maturi RK, et al; Ozurdex® ERIE Study Group. Dexamethasone intravitreal implant as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration: a multicenter randomized controlled trial. *Ophthalmologica*. 2015;234(1):40–54.
24. Rezar-Dreindl S, Eibenberger K, Buehl W, et al. Role of additional dexamethasone for the management of persistent or recurrent neovascular age-related macular degeneration under ranibizumab treatment. *Retina*. 2017;37(5):962–970.
25. Chaudhary V, Barbosa J, Lam WC, et al. Ozurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study). *Can J Ophthalmol*. 2016;51(4):302–305.
26. Shelsta HN, Jampol LM. Pharmacologic therapy of pseudophakic cystoid macular edema: 2010 update. *Retina*. 2011;31(1):4–12.
27. Sivaprasad S, Bunce C, Wormland R. Non-steroidal anti-inflammatory agents for cystoid macular edema following cataract surgery: a systematic review. *Br J Ophthalmol*. 2005;89(11):1420–1422.
28. Catier A, Tadayoni R, Massin P, Gaudric A. Advantages of acetazolamide associated with anti-inflammatory medications in postoperative treatment of macular edema. *J Fr Ophthalmol*. 2005;28(10): 1027–1031.
29. Spitzer MS, Ziemssen F, Yoeruek E, Petermeier K, Aisenbrey S, Szurman P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. *J Cataract Refract Surg*. 2008;34(1):70–75.
30. Deuter CM, Gelissen F, Stübiger N, Zierhut M, Doycheva D. Successful treatment of chronic pseudophakic macular edema (Irvine-Gass syndrome) with interferon alpha: a report of three cases. *Ocul Immunol Inflamm*. 2011;19(3):216–218.
31. Wu L, Arevalo JF, Hernandez-Bogantes E, Roca JA. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group. *Int Ophthalmol*. 2012;32(3):235–243.
32. Thach AB, Dugel PU, Flindall RJ. A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to topical medications. *Ophthalmology*. 1997;104(12): 2003–2008.
33. Williams GA, Haller JA, Kuppermann BD, et al; Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. *Am J Ophthalmol*. 2009;147(6):1048–1054.
34. Meyer LM, Schönfeld CL. Cystoid macular edema after complicated cataract surgery resolved by an intravitreal dexamethasone 0.7-mg implant. *Case Rep Ophthalmol*. 2011;2(3):319–322.
35. Dutra Medeiros M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome. *Invest Ophthalmol Vis Sci*. 2013;54(5):3320–3324.
36. Brynskov T, Laugesen CS, Halborg J, Kemp H, Sørensen TL. Long-standing refractory pseudophakic cystoid macular edema resolved using intravitreal 0.7 mg dexamethasone implants. *Clin Ophthalmol*. 2013;7:1171–1174.
37. Fenicia V, Balestrieri M, Perdicchi A, MauriziEnrici M, DelleFave M, Recupero SM. Intravitreal injection of dexamethasone implant and ranibizumab in cystoid macular edema in the course of Irvine-Gass syndrome. *Case Rep Ophthalmol*. 2014;5(2):243–248.
38. Dang Y, Mu Y, Li L, et al. Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients. *Drug Des Devel Ther*. 2014;8:1441–1449.
39. Furino C, Boscia F, Recchimurzo N, Sborgia C, Alessio G. Intravitreal dexamethasone implant for macular edema following uncomplicated phacoemulsification. *Eur J Ophthalmol*. 2014;24(3):387–391.
40. Al Zamil WM. Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema. *Saudi J Ophthalmol*. 2015;29(2):130–134.
41. Khurana RN, Palmer JD, Porco TC, Wieland MR. Dexamethasone intravitreal implant for pseudophakic cystoid macular edema in patients with diabetes. *Ophthalmic Surg Lasers Imaging Retina*. 2015; 46(1):56–61.
42. Ortega-Evangelio L, Diago Sempere T. Study of the effect of intravitreal dexamethasone implant in pseudophakic macular edema. Preliminary. *Arch Soc Esp Oftalmol*. 2015;90(7):303–307.
43. Mylonas G, Georgopoulos M, Malamos P, et al; Macula Study Group Vienna. Comparison of dexamethasone intravitreal implant with conventional triamcinolone in patients with postoperative cystoid macular edema. *Curr Eye Res*. 2016;9:1–5.
44. Belloq D, Pierre-Kahn V, Matonti F, et al. Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study. *Br J Ophthalmol*. 2017;101:333–341.
45. Sacchi M, Villani E, Gilardoni F, Nucci P. Efficacy of intravitreal dexamethasone implant for prostaglandin-induced refractory pseudophakic cystoid macular edema: case report and review of the literature. *Clin Ophthalmol*. 2014;8:1253–1257.
46. Turell ME, Singh AD. Vascular tumors of the retina and choroid: diagnosis and treatment. *Middle East Afr J Ophthalmol*. 2010;17(3): 191–200.
47. Yeh S, Wilson DJ. Pars plana vitrectomy and endoresection of a retinal vasoproliferative tumor. *Arch Ophthalmol*. 2010;128(9):1196–1199.
48. Cebeci Z, Oray M, Tuncer S, Tugal Tutkun I, Kir N. Intravitreal dexamethasone implant (Ozurdex) and photodynamic therapy for vasoproliferative retinal tumours. *Can J Ophthalmol*. 2014;49(4): e83–e84.
49. Yannuzzi LAI, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic macular telangiectasia. *Arch Ophthalmol*. 2006;124(4): 450–460.
50. Park DW, Schatz H, McDonald HR, Johnson RN. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasia. *Ophthalmology*. 1997;104(11):1838–1846.
51. De Lahitte GD, Cohen SY, Gaudric A. Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasia without subretinal neovascularization. *Am J Ophthalmol*. 2004;138(5):892–894.

52. Takayama KI, Ooto S, Tamura H, et al. Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia. *Eye*. 2010;24(9):1492–1497.
53. Terauchi G, Matsumoto CS, Shinoda K, et al. Pars plana vitrectomy combined with focal endolaser photocoagulation for idiopathic macular telangiectasia. *Case Rep Med*. 2014;2014:786578.
54. Wu L, Evans T, Arévalo JF, et al. Long-term effect of intravitreal triamcinolone in the nonproliferative stage of type II idiopathic parafoveal telangiectasia. *Retina*. 2008;28(2):314–319.
55. Sandali O, Akesbi J, Rodallec T, Laroche L, Nordmann JP. Dexamethasone implant for the treatment of edema related to idiopathic macular telangiectasia. *Can J Ophthalmol*. 2013;48(4):e78–e80.
56. Loutfi M, Papatomas T, Kamal A. Macular oedema related to idiopathic macular telangiectasia type 1 treated with dexamethasone intravitreal implant (ozurdex). *Case Rep Ophthalmol Med*. 2014;2014:231913.
57. Sigler EJ, Randolph JC, Calzada JI, Wilson MW, Haik BG. Current management of Coats disease. *Surv Ophthalmol*. 2014;59(1):30–46.
58. Ghazi NG, Al Shamsi H, Larsson J, Abboud E. Intravitreal triamcinolone in Coats' disease. *Ophthalmology*. 2012;119(3):648–649.
59. Chaudhary KM, Mititelu M, Lieberman RM. An evidence-based review of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 2. Coats' disease, Best disease, and uveitis with childhood neovascularization. *J Pediatr Ophthalmol Strabismus*. 2013;50(1):11–19.
60. Saatci AO, Doruk HC, Yaman A. Intravitreal dexamethasone implant (ozurdex) in Coats' disease. *Case Rep Ophthalmol*. 2013;4(3):122–128.
61. Martínez-Castillo S, Gallego-Pinazo R, Dolz-Marco R, et al. Adult Coats' disease successfully managed with the dexamethasone intravitreal implant (ozurdex®) combined with retinal photocoagulation. *Case Rep Ophthalmol*. 2012;3(1):123–127.
62. Lei S, Lam WC. Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children. *Can J Ophthalmol*. 2015;50(3):236–241.
63. Baillif S, Maschi C, Gastaud P, Caujolle JP. Intravitreal dexamethasone 0.7-mg implant for radiation macular edema after proton beam therapy for choroidal melanoma. *Retina*. 2013;33(9):1784–1790.
64. Caminal JM, Flores-Moreno I, Arias L, et al. Intravitreal dexamethasone implant for radiation maculopathy secondary to plaque brachytherapy in choroidal melanoma. *Retina*. 2015;35(9):1890–1897.
65. Russo A, Avitabile T, Uva M, et al. Radiation macular edema after Ru-106 plaque brachytherapy for choroidal melanoma resolved by an intravitreal dexamethasone 0.7-mg implant. *Case Rep Ophthalmol*. 2012;3(1):71–76.
66. Bui KM, Chow CC, Mieler WF. Treatment of recalcitrant radiation maculopathy using intravitreal dexamethasone (Ozurdex) implant. *Retin Cases Brief Rep*. 2014;8(3):167–170.
67. Seibel I, Hager A, Riechardt AI, Davids AM, Böker A, Jousen AM. Antiangiogenic or corticosteroid treatment in patients with radiation maculopathy after proton beam therapy for uveal melanoma. *Am J Ophthalmol*. 2016;168:31–39.
68. Tarmann L, Langmann G, Mayer C, Weger M, Haas A, Wackernagel W. Ozurdex® reduces the retinal thickness in radiation maculopathy refractory to bevacizumab. *Acta Ophthalmol*. 2014;92(8):694–696.
69. Yoshida N, Ikeda Y, Notomi S, et al. Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. *Ophthalmology*. 2013;120(1):e5–e12.
70. Heckenlively JR, Jordan BL, Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. *Am J Ophthalmol*. 1999;127(5):565–573.
71. Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. *Arch Ophthalmol*. 1988;106(9):1190–1195.
72. García-Arumí J, Martínez V, Sararols L, Corcostegui B. Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa. *Ophthalmology*. 2003;110(6):1164–1169.
73. Yuzbasioglu E, Artunay O, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa. *Curr Eye Res*. 2009;34(3):231–237.
74. Sallum JM, Farah ME, Saraiva VS. Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide: case report. *Adv Exp Med Biol*. 2003;533:79–81.
75. Ozdemir H, Karacorlu M, Karacorlu S. Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. *Acta Ophthalmol Scand*. 2005;83(2):248–251.
76. Scroli L, Morara M, Meduri A, et al. Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. *Arch Ophthalmol*. 2007;125(6):759–764.
77. Srour M, Querques G, Leveziel N, et al. Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa. *Graefes Arch Clin Exp Ophthalmol*. 2013;251(6):1501–1506.
78. Ahn SJ, Kim KE, Woo SJ, Park KH. The effect of an intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa: a case report and literature review. *Ophthalmic Surg Lasers Imaging Retina*. 2014;45(2):160–164.
79. Saatci AO, Selver OB, Seymenoglu G, Yaman A. Bilateral intravitreal dexamethasone implant for retinitis pigmentosa-related macular edema. *Case Rep Ophthalmol*. 2013;4(1):53–58.
80. Patil L, Lotery AJ. Coat's-like exudation in rhodopsin retinitis pigmentosa: successful treatment with an intravitreal dexamethasone implant. *Eye (Lond)*. 2014;28(4):449–451.
81. Furino C, Boscia F, Recchimurzo N, Sborgia C, Alessio G. Intravitreal dexamethasone implant for refractory macular edema secondary to vitrectomy for macular pucker. *Retina*. 2014;34(8):1612–1616.
82. Taney LS, Baurnal CR, Duker JS. Sustained-release dexamethasone intravitreal implant for persistent macular edema after vitrectomy for epiretinal membrane. *Ophthalmic Surg Lasers Imaging Retina*. 2015;46(2):224–228.
83. Merkoudis N, Granstam E. Treatment of postoperative cystoid macular oedema with dexamethasone intravitreal implant in a vitrectomized eye – a case report. *Acta Ophthalmol*. 2013;91(3):238–239.
84. Georgalas I, Petrou P, Papakonstantinou D, Droumouchtsis V, Tservakis I. Post-operative refractory cystoid macular edema in a vitrectomized eye treated with slow-release dexamethasone implant (Ozurdex). *Cutan Ocul Toxicol*. 2015;34(3):257–259.
85. Bonfiglio V, Fallico MR, Russo A, et al. Intravitreal dexamethasone implant for cystoid macular edema and inflammation after scleral buckling. *Eur J Ophthalmol*. 2015;25(5):e98–e100.
86. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology*. 2011;118(12):2453–2460.
87. Lowder CI, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. *Arch Ophthalmol*. 2011;129(5):545–553.

## Drug Design, Development and Therapy

### Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>

Dovepress

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.